Bellmunt J., Valderrama B.P., Puente J., Grande E., Bolós M.V., Lainez N., Vázquez S., Maroto P., Climent M.Á., Garcia del Muro X., Arranz J.Á., Durán I.. Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2022; 174DOI:10.1016/j.critrevonc.2022.103683. PMID:35439541. IF:6.200(Q1/3D).

Aguado-Flor E., Fuentes-Raspall M.J., Gonzalo R., Alonso C., Ramón y Cajal T., Fisas D., Seoane A., Sánchez-Pla Á., Giralt J., Díez O., Gutiérrez-Enríquez S.. Cell Senescence-Related Pathways Are Enriched in Breast Cancer Patients With Late Toxicity After Radiotherapy and Low Radiation-Induced Lymphocyte Apoptosis. Frontiers in Oncology. 2022; 12DOI:10.3389/fonc.2022.825703. PMID:35686103. IF:4.700(Q2/4D).

Provencio M., Serna-Blasco R., Nadal E., Insa A., García-Campelo M.R., Casal Rubio J., Dómine M., Majem M., Rodríguez-Abreu D., Martínez-Martí A., De Castro Carpeño J., Cobo M., López Vivanco G., Del Barco E., Bernabé Caro R., Viñolas N., Barneto Aranda I., Viteri S., Pereira E., Royuela A., Calvo V., Martín-López J., García-García F., Casarrubios M., Franco F., Sánchez-Herrero E., Massuti B., Cruz-Bermúdez A., Romero A.. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial). JOURNAL OF CLINICAL ONCOLOGY. 2022; 71DOI:10.1200/JCO.21.02660. PMID:35576508. IF:45.300(Q1/1D).

Riudavets M., Auclin E., Mosteiro M., Dempsey N., Majem M., Lobefaro R., López-Castro R., Bosch-Barrera J., Pilotto S., Escalera E., Tagliamento M., Mosquera J., Zalcman G., Aboubakar-Nana F., Ponce S., Dal Maso A., Spotti M., Mielgo-Rubio X., Mussat E., Reyes R., Benítez J.-C., Lupinacci L., Duchemann B., De Giglio A., Blaquier J., Audigier-Valette C., Scheffler M., Nadal E., Lopes G., Signorelli D., Garcia-Campelo R., Menis J., Bluthgen V., Campayo M., Recondo G., Besse B., Planchard D., Mezquita L.. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations. EUROPEAN JOURNAL OF CANCER. 2022; 167DOI:10.1016/j.ejca.2022.02.014. PMID:35307254. IF:8.400(Q1/2D).

Bernabé-Caro R., Garrido P., García-Campelo R., Palmero R., Artal Á., Bayona C., Rodríguez-Abreu D., López-Brea M., Paredes A., Vicente D., Torres J.M.S., Majem M., Diz P., Gordo R., Coca M., de Castro J.. Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program. Oncotarget. 2022; 13(1)DOI:10.18632/oncotarget.28244. PMID:. IF:(Q/D).

Peters S., Pujol J.-L., Dafni U., Dómine M., Popat S., Reck M., Andrade J., Becker A., Moro-Sibilot D., Curioni-Fontecedro A., Molinier O., Nackaerts K., Insa Mollá A., Gervais R., López Vivanco G., Madelaine J., Mazieres J., Faehling M., Griesinger F., Majem M., González Larriba J.L., Provencio Pulla M., Vervita K., Roschitzki-Voser H., Ruepp B., Mitchell P., Stahel R.A., Le Pechoux C., De Ruysscher D., Stahel R., Hiltbrunner A., Pardo-Contreras M., Gasca-Ruchti A., Giacomelli N., Kammler R., Marti N., Pfister R., Piguet A.C., Roux S., Troesch S., Schneider M., Schweri R., Zigomo I., Tsourti Z., Zygoura P., Tsouprou S., Kassapian M., Dimopoulou G., Andriakopoulou C., Morin F., Amour E., Mariaule G., Archirel N., Fernandez M., Pereira E., Benito L., Lopez K., Hernández A., Chinchen S., Jurkovic H., Livingstone A., Mitchell J., Walker M., Ng S., Steer C., Briscoe K., Saqib A., Abdi E., Houghton B., O'Byrne K., Chittajallu B.R., Hughes B.G., Black A., Werner H., Zalcman G., Vaylet F., Merle P., Monnet I., Girard N., Souquet P.-J., Barlesi F., Debieuvre D., Senellart H., Poudenx M., Dixmier A., Pouessel D., Cadranel J., Lena H., Quoix E., Friard S., Audigier-Valette C., Pichon E., Kokowski K., Kirchen H., Tufman A., De-Colle C., de Langen J., Insa A., Massutí B., Pulla M.P., Aix S.P., Villanueva N., Vivanco G.L., Franks K., Califano R.. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. ANNALS OF ONCOLOGY. 2022; 33(1)DOI:10.1016/j.annonc.2021.09.011. PMID:34562610. IF:50.500(Q1/1D).

López-Laguna H, Voltà-Durán E, Parladé E, Villaverde A, Vázquez E, Unzueta U. Insights on the emerging biotechnology of histidine-rich peptides. BIOTECHNOLOGY ADVANCES. 2022; 54DOI:10.1016/j.biotechadv.2021.107817. PMID:34418503. IF:16.000(Q1/1D).

Pasquali, S, Palmerini, E, Quagliuolo, V, Martin-Broto, J, Lopez-Pousa, A, Grignani, G, Brunello, A, Blay, JY, Tendero, O, Diaz-Beveridge, R, Ferraresi, V, Lugowska, I, Infante, G, Braglia, L, Merlo, DF, Fontana, V, Marchesi, E, Donati, DM, Palassini, E, Bianchi, G, Marrari, A, Morosi, C, Stacchiotti, S, Bague, S, Coindre, JM, Dei Tos, AP, Picci, P, Bruzzi, P, Miceli, R, Casali, PG, Gronchi, A. Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial. CANCER. 2022; 128(1)DOI:10.1002/cncr.33895. PMID:34643947. IF:6.200(Q1/3D).